AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03473028 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transvaginal ultrasound guided embryo transfer
Description: 400 female with body mass index more than 30 undergo transvaginal ultrasound guided embryo transfer
Study NCT03224962 — intervention group
Intervention type: DEVICE
Intervention: fluorescence camera
Description: drug - diagnostic test
Study NCT03433066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced platelet-rich fibrin mixed with biphasic alloplast
Description: mucoperiosteal flaps will be reflected to expose the defects , which will be debrided properly and finally filled with the freshly prepared Advanced platelet-rich fibrin mixed with the biphasic alloplast.
Study NCT01849081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Subjects in the intervention arm will be treated with continuous positive airway pressure (CPAP) device at night.
Study NCT01849081 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LIfestyle
Description: Subjects will undergo 12 weeks of dietary counseling.
Study NCT02177487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/hydrochlorothiazide
Study NCT03433066 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic alloplast mixed with saline
Description: mucoperiosteal flap will be reflected to expose and clean the intrabony defect ,then it will be filled with biphasic alloplast mixed with saline.
Study NCT00467844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-024
Description: 1 mg GTx 024
Study NCT00467844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-024
Description: 3 mg GTx-024
Study NCT00467844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT01593982 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: 20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex
Study NCT01593982 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: 20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex
Study NCT02580162 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FBT for Pediatric Weight Management by Professionals
Description: This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is delivered by PROFESSIONAL interventionists.
Study NCT02580162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FBT for Pediatric Weight Management by Professionals
Description: This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is delivered by PROFESSIONAL interventionists.
Study NCT02580162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FBT for Pediatric Weight Management by Peers
Description: This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is provided by PEER interventionists.
Study NCT02580162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Interventionists
Description: Parents who receive FBT complete 6 weeks of training and then serve as peer interventionists to a new group of families.
Study NCT00688038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Ablation
Description: Laser ablation procedure taking about 1-3 hours, depending on the size and location of the tumor.
Study NCT00688038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Thermal Imaging
Description: MRTI will be used to monitor the temperature within the ablation zone during the laser ablation.
Study NCT00440323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-649868
Description: SB-649868 tablets will be available with dose strength of 5 and 25 mg.
Study NCT06308861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single administration Dmg dose Group
Description: Orally, Dmg tablet single administration
Study NCT06308861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single administration Emg dose Group
Description: Orally, Emg tablet single administration
Study NCT06308861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single administration Amg dose Group-Placebo
Description: Orally, Placebo Amg tablet, single administration
Study NCT06308861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single administration Bmg dose Group-Placebo
Description: Orally, Placebo Bmg tablet, single administration
Study NCT06308861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single administration Cmg dose Group-Placebo
Description: Orally, Placebo Cmg tablet, single administration
Study NCT06308861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single administration Dmg dose Group-Placebo
Description: Orally, Placebo Dmg tablet, single administration
Study NCT06308861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single administration Emg dose Group-Placebo
Description: Orally, Placebo Emg tablet, single administration
Study NCT06308861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple administration Amg dose group
Description: Orally, Amg 1 tablet, once a day for 3 days, multiple administration
Study NCT06308861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple administration Bmg dose group
Description: Orally, Bmg 1 tablet, once a day for 3 days, multiple administration
Study NCT06308861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple administration Cmg dose group
Description: Orally, Cmg 1 tablet, once a day for 3 days, multiple administration
Study NCT06308861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple administration Dmg dose group
Description: Orally, Dmg 1 tablet, once a day for 3 days, multiple administration
Study NCT06308861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple administration Emg dose group
Description: Orally, Emg 1 tablet, once a day for 3 days, multiple administration
Study NCT06308861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple administration Amg dose group - Placebo
Description: Orally, Placebo Amg 1 tablet, once a day for 3 days, multiple administration
Study NCT06308861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple administration Bmg dose group - Placebo
Description: Orally, Placebo Bmg 1 tablet, once a day for 3 days, multiple administration
Study NCT06308861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple administration Cmg dose group - Placebo
Description: Orally, Placebo Cmg 1 tablet, once a day for 3 days, multiple administration
Study NCT06308861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple administration Dmg dose group - Placebo
Description: Orally, Placebo Dmg 1 tablet, once a day for 3 days, multiple administration
Study NCT06308861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple administration Emg dose group - Placebo
Description: Orally, Placebo Emg 1 tablet, once a day for 3 days, multiple administration
Study NCT02339558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02339558 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT00979043 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Weight-loss
Description: The goal of the dietary weight-loss intervention was to produce and maintain a mean weight-loss of 5% initial body weight during the 18-month intervention, using dietary counseling and behavior modification.
Study NCT00979043 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Participants participated in resistance training (15 minutes) and aerobic exercise (30 minutes) 3d/week for 18-months. The first 4-months of the exercise training were facility-based. After 4-months, participants were allowed to transition to a home-based intervention if they chose to.
Study NCT01519258 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Support ventilation
Description: Patients will receive usual care during the period of ventilation on the Pressure Support. The same ventilator, the Servoi (maquet, Sweden) will be used.
Study NCT01519258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA
Description: Patients will be ventilated with NAVA for 15 minutes. Back up settings in pressure support mode will be set in case the esophageal catheter is misplaced, and back up settings in pressure control ventilation will be set in case no inspiratory efforts are detected for longer than 15 seconds
Study NCT01391273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost solution 0.03%
Description: One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
Study NCT01391273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bimatoprost vehicle solution
Description: One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
Study NCT04198363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Vonoprazan Tablets
Study NCT04198363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin Capsules
Study NCT04198363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin Capsules
Study NCT04198363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Clarithromycin Tablets
Study NCT04198363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin Tablets
Study NCT04198363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Potassium citrate
Description: Bismuth Potassium citrate
Study NCT04198363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium citrate
Description: Bismuth Potassium citrate
Study NCT04198363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole Tablets
Study NCT03372187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIET-MS
Description: Following the completion of testing, all 20 participants will be placed into the DIET-MS group and will follow the prescribed diet plan for 12 weeks. At the end of the 12 weeks, the participants will return to complete follow up testing.
Study NCT06742541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Collamer Lens (ICL) followed by a planned adjunctive LASIK postoperatively
Description: Planned surgery to receive a spherical Implantable Collamer Lens (ICL) followed by a planned adjunctive LASIK postoperatively
Study NCT03571282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conbercept
Description: After three monthly injections of conbercept, if no effects was seen in the patients, the patients will receive rescue treatments such as photodynamic therapy (in the macular) or laser photocoagulation (outside the macular).
Study NCT00440323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem capsules will be available with dose strength of 10 mg.
Study NCT02233764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FeZnPM
Description: Iron and zinc biofortified pearl millet will be consumed three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
Study NCT02233764 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CtrlPM
Description: Conventional pearl millet will be consumed three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
Study NCT01640106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: 800 mg Omega 3 daily (600 mg DHA/200 mg EPA)
Study NCT01640106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a combination of dietary plant-based oils in a paste containing no Omega-3 (EPA or DHA)
Study NCT03530046 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: High SID fluid
Description: The fluid will be given to the patient at a rate prescribed by the treating physician according to clinical response for a period of 2 hours or up to maximum 30ml/kg fluid is given, whichever is earlier.
Study NCT03530046 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Hartmann's solution
Description: The fluid will be given to the patient at a rate prescribed by the treating physician according to clinical response for a period of 2 hours or up to maximum 30ml/kg fluid is given, whichever is earlier.
Study NCT03760471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidenced-based symptom management and coping intervention
Description: The intervention visits will focus on coping and the following symptoms prevalent during CRT: (1) pain and mucositis, (2) nausea, (3) constipation, (4) fatigue, (5) sleep disturbances, (6) xerostomia, (7) thick mucus, and (8) depression
Study NCT00440323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet matching SB-649868 or Placebo capsule matching Zolpidem will be available.
Study NCT00358163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787/ZK 222584
Description: Taken in tablet form daily
Study NCT00358163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given as a 3-hour infusion once every 21 days
Study NCT00861185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: senicapoc
Description: Loading Dose: 80 mg twice daily x 3 days Maintenance Dose: 40 mg daily for remainder of the treatment period (total 4 weeks)
Study NCT00861185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo looks identical to active study medication and will be dosed according to the same dosing regimen
Study NCT01919307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: The NADA Protocol for auricular acupuncture will be performed by the PI, a certified NADA protocol practitioner, using sterile, single-use, Seiren 0.22mm, one cm disposable detox needles. Both ears will be sterilized with alcohol swabs. There will be no electrical or other stimulation performed. Needles will be placed subcutaneously with one half twirl upon insertion to the following 5 points (in order per ear): Sympathetic, Shen Men, Kidney, Liver, Lung. Needles will remain in place for 40 minutes and will then be removed in the same order as they were inserted. Needles that become dislodged will be replaced per typical NADA protocol.
Study NCT01209858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel and Microgynon-30
Description: Part A: Microgynon-30 single oral dose on Day 1 Period 1 and Day 35 Period 2; perampanel oral daily dose starting at 4 mg per day Period 2 from Days 1 through 35 and titrated weekly.
Study NCT01209858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel and Microgynon-30
Description: Part B: Perampanel single oral dose of 6 mg on Day 1 Period 1 and Day 21 Period 2; Microgynon-30 orally from Day 1 through Day 21 of Period 2.
Study NCT01928979 — intervention group
Intervention type: OTHER
Intervention: no drug
Description: Patients who suffered from hemodynamically stable nonvalvular AF or atrial flutter and had a diagnosed LA/ LAA thrombus between January 1st, 2011 and December 31st, 2012
Study NCT02682810 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DNA PCR HIV diagnostic test
Description: standard of care
Study NCT02682810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alere Q
Description: POC diagnostic Alere Q qualitative test (along with a DBS drawn for confirmatory DNA PCR)
Study NCT03570424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrient support to HIIT
Description: 3 groups of young (aged 18-35 y), healthy, recreationally active, aerobically untrained (VO2max \<50 ml.kg.min-1) males will undertake 3 weeks (9 sessions) of HIIT under different nutrient conditions following >10h overnight fast: i) Placebo: Fasted artificially flavoured and textured placebo 45 minutes prior to exercise; ii) Whey protein 45 minutes prior to exercise; iii) Whey protein hydrolysate 45 minutes prior to exercise).
Study NCT03570424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 groups of young (aged 18-35 y), healthy, recreationally active, aerobically untrained (VO2max \<50 ml.kg.min-1) males will undertake 3 weeks (9 sessions) of HIIT under different nutrient conditions following >10h overnight fast: i) Fasted artificially flavoured and textured placebo 45 minutes prior to exercise; ii) Fed Whey protein 45 minutes prior to exercise; iii) Fed Whey protein hydrolysate 45 minutes prior to exercise).
Study NCT04093999 — intervention group
Intervention type: PROCEDURE
Intervention: Sensory nerve coaptation
Description: A recipient sensory nerve branch of the 11th-12th intercostal nerve was reattached to a donor nerve in the chest area. The anterior cutaneous branch of the second or third intercostal nerve was used as the donor nerve. Direct, end-to-end nerve coaptation was performed.
Study NCT02661477 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pegylated interferon alfa 2
Study NCT02661477 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: 0,9% natrium chlorine solution
Study NCT02287519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Session
Study NCT02287519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Coaching Session
Study NCT02287519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Webinar
Study NCT03559309 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Magnet Resonance Tomography, Carotid Arteries Sonography, Flow-mediated Dilation, Fat-tolerance Test, Laboratory Testing
Description: Patients treated with Alirocumab in the clinical routine will have additional diagnostic tests as stated above. The clinical trial will be conducted as an open label, single arm study. The diagnostic tests will be done at baseline (BL) and after 10 weeks of treatment (W10) with Alirocumab.
Study NCT05484947 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Elisa HIV testing
Description: HIV testing on a voluntary basis
Study NCT04281719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application (working name: Bright Path)
Description: The Bright Path web-based mobile application is designed to target co-occurring problems, enhance patient treatment engagement, and contribute to lasting improvements in teens' mental health. The central hypothesis is that developmentally tailored mobile applications that incorporate evidence-based treatment principles can facilitate increased patient engagement in and between sessions, thus, improving the efficiency, efficacy, and reach of treatments for this highly vulnerable population.
Study NCT00872157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMTP-11
Description: Starting Dose of 6 mg/m2 by vein over 2 hours on Days 1, 8, 15, and 22.
Study NCT04183673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser therapy-cryo thermal therapy
Description: 5 days per week, 3 weeks, sessions including laser therapy + cryo therapy followed by usual rehabilitation
Study NCT01334853 — intervention group
Intervention type: OTHER
Intervention: No drug will be used
Description: Biomarker
Study NCT03718260 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]-DCFPyL PET/ CT scan (PSMA PET)
Description: Participants will undergo re-staging with \[18F\]-DCFPyL PET/CT Scan (PSMA PET).
Study NCT02659293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: * Cycle 1: 15 mg days 1-21~* Cycles 2-4: 25 mg days 1-21 if tolerated, otherwise continue at lower dose~* Cycles 5 and beyond: best tolerated dose days 1-21